摘要
目的:探讨利格列汀联合阿卡波糖治疗老年糖尿病(2型)的临床效果和不良反应。方法:选择我院老年糖尿病(2型)50例分为对照组和观察组各25例,对照组给予阿卡波糖治疗,观察组接受利格列汀+阿卡波糖治疗,治疗4个月后,比较两组治疗效果和不良反应。结果:与治疗前相比,治疗后对照组与观察组FPG、2hPG、HbAlc均显著降低,差异具有统计学意义(P<0.05);观察组与对照组比较,FPG、2hPG、HbAlc下降更明显,差异具有统计学意义(P<0.05);而不良反应两组间差异无统计学意义(P>0.05);治疗后,观察组与对照组患者的BMI差异无统计学意义(P>0.05)。结论:与阿卡波糖相比,利格列汀联合阿卡波糖在改善2型糖尿患者的FPG、2hPG及HbAlc方面疗效更好,利格列汀和阿卡波糖的临床安全性均较高,且都不会引起患者体重增加和低血糖。
Objective：To investigate the clinical efficacy and the adverse reaction of trajenta combined with acarbose in the treatment of senile diabetes mellitus（type 2）.Methods：50patients with senile type 2diabetes in our hospital were randomized into the observation group and the control group with 25 cases each.The control group were treated with acarbose,while the observation group were with trajenta combined with acarbose.After 4months＇ treatment,the clinical efficacy and adverse reaction between both groups were compared.Results：Compared with patients before the treatment,FPG,2hPG and HbAlc in both groups were significantly decreased after the treatment,which were of statistical differences（P〈0.05）;compared with the control group,FPG,2hPG,and HbAlc in the observation group decreased more significantly,which was of statistical differnce（P〈0.05）;as for the adverse effect,there was no difference between both groups（P〉0.05）;and after the treatment,there was no statistical difference of BMI between both groups（P〉0.05）.Conclusion：Compared with the acarbose treatment,trajenta combined with acarbose are more effective in improving FPG,2hPG and HbAlc of patients with type 2diabetes.Moreover,they are safer and will not lead to gaining weight and hypoglycemia of patients.
出处
《华夏医学》
CAS
2015年第2期33-35,共3页
Acta Medicinae Sinica
